Print…

Procurou por: Thymine


116  resultados encontrados

SearchResultCount:"116"

Sort Results

Visualização em Lista Easy View (new)

Classifique os resultados da pesquisa

Código de Artigo: (BOSSBS-8288R-A350)
Fornecedor: Bioss
Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
UOM: 1 * 100 µl


Código de Artigo: (BOSSBS-8288R-CY5)
Fornecedor: Bioss
Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
UOM: 1 * 100 µl


Código de Artigo: (BOSSBS-8288R-CY3)
Fornecedor: Bioss
Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
UOM: 1 * 100 µl


Fornecedor: TCI
Descrição: 3'-Azido-3'-deoxythymidine ≥98.0% (by titrimetric analysis)

Fornecedor: Thermo Fisher Scientific
Descrição: 3'-Azido-3'-deoxythymidine 98%
Código de Artigo: (APOSBIT2044-25G)
Fornecedor: Apollo Scientific
Descrição: Timidina (2'-desoxitimidina)
UOM: 1 * 25 g


Código de Artigo: (BOSSBS-8288R-FITC)
Fornecedor: Bioss
Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
UOM: 1 * 100 µl


Código de Artigo: (BOSSBS-8288R-A680)
Fornecedor: Bioss
Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterised by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
UOM: 1 * 100 µl


Código de Artigo: (BOSSBS-2950R-A647)
Fornecedor: Bioss
Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.
UOM: 1 * 100 µl


Fornecedor: Thermo Fisher Scientific
Descrição: Timidina (2'-desoxitimidina) ≥99%
Fornecedor: Apollo Scientific
Descrição: A potent & selective inhibitor of HIV-1 replication.

Código de Artigo: (BOSSBS-2950R-CY3)
Fornecedor: Bioss
Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.
UOM: 1 * 100 µl


Fornecedor: Thermo Fisher Scientific
Descrição: 2',3'-Didehydro-3'-deoxythymidine 98%
Código de Artigo: (BOSSBS-2950R-A555)
Fornecedor: Bioss
Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.
UOM: 1 * 100 µl


Código de Artigo: (BOSSBS-2950R-A350)
Fornecedor: Bioss
Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.
UOM: 1 * 100 µl


Código de Artigo: (BOSSBS-2950R-FITC)
Fornecedor: Bioss
Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.
UOM: 1 * 100 µl


Preço sob consulta
O stock para este item é limitado. Por favor, certifique-se de que efetuou o seu login para visualizar o stock disponível. Se a call ainda é exibida e precisar de ajuda, por favor, ligue para 213 600 770
O stock para este item é limitado. Por favor, certifique-se de que efetuou o seu login para visualizar o stock disponível. Se a call está visível e precisar de ajuda, por favor, ligue para 213 600 770
Este produto é sujeito a regulamentação especifica.
Em caso de encomenda, será contactado a solicitar documentação complementar necessária e/ou obrigatória (licença, autorização ou declaração de uso final) para a continuidade do pedido. Agradecemos a vossa compreensão
Este produto é sujeito a regulamentação especifica.
Em caso de encomenda, será contactado a solicitar documentação complementar necessária e/ou obrigatória (licença, autorização ou declaração de uso final) para a continuidade do pedido. Agradecemos a vossa compreensão.
Este produto está bloqueado. Para obter mais informações, contacte a VWR através do número 213 600 770.
O produto pretendido já não se encontra disponível. O produto indicado é um substituto.
Este produto encontra-se em rutura de stock. Poderá encontrar alternativas pesquisando pelo código de artigo indicado acima. Se precisar de ajuda, por favor contacte a VWR através do 213 600 770.
17 - 32 of 116
no targeter for Bottom